Bovine colostrum for prevention of recurrent urinary tract infections in susceptible children: A randomized controlled trial

Table 5 Frequency of gastrointestinal and respiratory infection among study groups, n (%)

Time	Colostrum group (n = 30)	Placebo group (n = 30)	P value	RR (95%CI)
GIT/respiratory infections
Month-1	15 (50.0)	12 (40.0)	0.436	1.25 (0.71-2.20)
Month-2	3 (10.0)	18 (60.0)	< 0.001	0.17 (0.05-0.51)
Month-3	4 (13.3)	14 (46.7)	0.005	0.29 (0.11-0.77)
Month-4	4 (13.3)	13 (43.3)	0.010	0.31 (0.11-0.84)
Month-5	3 (10.0)	17 (56.7)	< 0.001	0.18 (0.06-0.54)
Month-6	3 (10.0)	11 (36.7)	0.015	0.27 (0.08-0.88)
Incidence	19 (63.3)	29 (96.7)	0.001	0.66 (0.50-0.87)
GIT infections
Month-1	7 (23.3)	6 (20.0)	0.754	1.17 (0.44-3.06)
Month-2	2 (6.7)	9 (30.0)	0.020	0.22 (0.05-0.94)
Month-3	1 (3.3)	7 (23.3)	0.052	0.14 (0.02-1.09)
Month-4	2 (6.7)	5 (16.7)	0.424	0.40 (0.08-1.90)
Month-5	1 (3.3)	8 (26.7)	0.026	0.13 (0.02-0.94)
Month-6	1 (3.3)	5 (16.7)	0.195	0.20 (0.02-1.61)
Incidence	9 (30.0)	18 (60.0)	0.020	0.50 (0.27-0.93)
Respiratory infection
Month-1	8 (26.7)	6 (20.0)	0.542	1.33 (0.53-3.38)
Month-2	1 (3.3)	9 (30.0)	0.006	0.11 (0.01-0.82)
Month-3	3 (10.0)	7 (23.3)	0.166	0.43 (0.12-1.50)
Month-4	2 (6.7)	8 (26.7)	0.038	0.25 (0.06-1.08)
Month-5	2 (6.7)	9 (30.0)	0.020	0.22 (0.05-0.94)
Month-6	2 (6.7)	6 (20.0)	0.254	0.33 (0.07-1.52)
Incidence	14 (46.7)	23 (76.7)	0.017	0.61 (0.40-0.94)

RR: Relative risk; GIT: Gastrointestinal.